Navigation Links
Improved Pharma now offers the detection of small amounts of amorphous material in crystalline samples

Detecting a small amount of a crystalline component in a predominantly amorphous material is relatively straight-forward, but the reverse situation can be quite daunting. Over the years, several methodologies have been developed to address this challenge. Below, Improved Pharma describes some of these approaches and announces advances of their own and also that of one of their primary collaborators, Excelsus Structure Solutions. 

In several of the early SSCI courses on Pharmaceutical Solids, the late David Grant advanced the microcalorimetric method for analyzing the amorphous content of crystalline samples. This method required that the amorphous material crystallized with a detectable energy response. This method is still utilized today and is described in USP 696. With the advent of powerful Synchrotron X-ray powder diffraction (S-XRPD) methods, several new approaches for analysis for amorphous material in a crystalline phase have been developed.

Three methods are of particular interest: (1) Methods based on pattern analysis that typically use software for spectral pattern analysis, (2) PDF-based methods, and (3) controlled measurements of S-XRPD data. The spectral pattern analysis method utilizes standard patterns of the crystalline and amorphous phases collected on a Synchrotron. This software-based approach fits the crystalline and amorphous standards to the observed data and calculates a percentage amorphous material. The PDF method has been advanced by our collaborators, Excelsus Structure Solutions. Excelsus has recently demonstrated that it was possible to perform quantitative phase analysis on a mixture of poorly- and non-crystalline excipients via conventional S-XRPD and pair distribution function analysis, provided that the experimental setup, data collection and analysis strategy were carefully optimized. A third method, optimized at Improved Pharma, involves collecting Synchrotron X-ray diffraction data under certain controlled conditions, and then performing mathematical techniques on the data to provide the reliable detection of amorphous materials. Currently, this approach is qualitative in nature, allowing for the ranking of multiple samples for their relative amorphous content. Improved Pharma is further developing the technique to provide quantitative information.

A fourth method utilizing the publicly available program AMORPH has been utilized for inorganic samples. AMORPH utilizes a new Bayesian statistical approach to interpreting X-ray di?raction results of samples with both crystalline and amorphous components (see Rowe and Brewer in Computers and Geosciences). AMORPH ?ts X-ray di?raction patterns with a mixture of narrow and wide components, simultaneously inferring all of the model parameters and quantifying their uncertainties. Unfortunately, to date, this program has not been utilized for drugs or organic materials.

Overall, due to techniques developed in-house and also by our collaborators, Improved Pharma’s problem-solving capabilities now extend to determining the amount of amorphous materials in crystalline materials. Contact us for problems involving crystalline and amorphous materials.

About Improved Pharma
Improved Pharma is a research and information company dedicated to improving pharmaceutical methods, formulations, and processes. Dr. Stephen Byrn and Sarah Byrn founded the company in 2006 after the successful acquisition of their first company, SSCI. Dr. Pamela Smith joined the company in 2018 after an 18-year tenure with SSCI. Improved Pharma offers services such as analytical testing, synchrotron-based formulation design, and expert consulting aiding the development and defense of intellectual property matters.

Read the full story at

Source: PRWeb
Copyright©2019 Vocus, Inc.
All rights reserved

Related biology news :

1. Improved Pharma to Speak at 69th Annual Meeting of the American Crystallographic Association
2. Improved Pharma Publishes Review Article in AAPS PharmSciTech
3. Abcam Collaborates with Visikol to Develop New Tools for Improved Tissue Clearing and 3D Imaging
4. Improved mouse model will accelerate research on potential Ebola vaccines, treatments
5. Improved electricity access has little impact on climate change
6. S-equol supplements associated with improved measures of reproductive health in postmenopausal women
7. Federal food program puts food on the table, but dietary quality could be improved
8. Plant variants point the way to improved biofuel production
9. Samtools CRAMS in support for improved compression formats
10. Developing an improved liposuction technique that melts fat
11. University of Toronto biologists pave the way for improved epilepsy treatments
Post Your Comments:
(Date:8/7/2020)... ... August 06, 2020 , ... Nine ... prestigious National STEM Scholar Program, a unique professional development program that provides advanced ... for middle school science teachers nationwide. , Created in partnership between the National ...
(Date:7/22/2020)... ... 21, 2020 , ... USDM Life Sciences , a ... a new solution to manage regulated workloads on Microsoft Azure. , Regulated biotechnology, ... complies with FDA and global regulations. USDM's new managed service for regulated workloads ...
(Date:7/4/2020)... ... July 03, 2020 , ... Aesthetics Biomedical (ABM), a ... awards for not only the products and treatments developed, but also the dedicated ... RF. All the brands built by ABM have received several honors already for ...
Breaking Biology News(10 mins):
(Date:7/10/2020)... ... July 09, 2020 , ... In most research using the ... pigment formation in zebrafish embryos, maintaining optical transparency to facilitate microscopic imaging. Over ... been using the zebrafish model to investigate the causes of leukaemia and its ...
(Date:7/7/2020)... ... July 06, 2020 , ... R3 International is now ... up to 200 million stem cells. Depending on the patient's condition, treatment may be ... US will die having some form of Alzheimers dementia, and the incidence continues to ...
(Date:7/1/2020)... ... June 29, 2020 , ... MedShift ... 40% in 2020, despite many obstacles created as a result of COVID-19. As ... for its partnered medical practices and medical manufacturers by expanding access to device ...
(Date:7/1/2020)... ... June 30, 2020 , ... ... launch of a new clinical diagnostics immuno-oncology service, TissueInsight . TissueInsight ... , “Flagship’s TissueInsight is a service that aids pathologists, oncologists, and immunologists ...
Breaking Biology Technology: